A loading dose of tamoxifen 100 mg/m
2 on day 1, followed by a maintenance dose of 20 mg daily, achieved mean
parent drug concentrations of greater than 150 ng/ml in 12 of 12 patients with metastatic breast cancer. This drug concentration was achieved on day 1 and maintained throughout the study period (28 days). This rapid achievement of steady-state serum concentrations may be of therapeutic benefit in the management of patients with tamoxifen-sensitive tumours.
Nolvadex is a trade mark property of Imperial Chemical Industries PLC